언어선택 ENG
KOR ENG
전체메뉴
전체메뉴 닫기

Leadership

Innovative Medicines based on
ImmunoModulatory Biologics

Our leadership team shares diverse industry knowledge and deep experiences covering the full value chain of biopharmaceutical new drug R&D.

Key executives

  • Gyongsik Ha Ph.D.

    President/CEO & Founder

  • Chihye Park Ph.D

    CDO / Head of Development dept.

  • Chungmin Lee Ph.D.

    CTO / Head of R&D Center

  • Insoo Jung Ph.D

    COO & CBO / Head of Business Operation

  • Wanjun Kim Master of Business A

    Chief of Management Support (CFO)

  • Jiyeon Hong Ph.D.

    Head of Business Development

  • Hong Jai Lee Ph.D.

    Leader of Platform Research

Scientific Advisory Board (SAB) members

  • Eunyoung Lee MD, Ph.D.

  • Chulho Park Ph.D.

닫기

Gyongsik Ha Ph.D.

President/CEO & Founder

Gyongsik founded IMBiologics in August 2020. He brings over 20 years of leadership in biotech and pharma, combined with rich experiences in clinical development, marketing, business development as well as R&D in pharmaceutical industry.

Background
  • Head of Bio Research Center at HK inno.N
  • BS/MS/PhD at Korea University
Key Performances
  • Led multiple IND/NDA of biologic drugs
  • Out-licensed a biosimilar to Japan/China
  • Led clinical development, drug pricing and marketing of multiple biologics
닫기

Chihye Park Ph.D

CDO / Head of Development dept.

Chihye joined IMB in 2021 as Chief Development Officer to lead preclinical and clinical development of IMB’s pipelines. She has over 15 years of experience in global development of biologics (US IND, CTA and NDA), covering from nonclinical phase to drug approval. Chihye completed her postdoctoral training at Harvard Medical School.

Background
  • CDO at Kine Sciences Co.,Ltd.
  • Head of Clinical Center at HK inno.N
  • Head of Drug Evaluation Center at HK inno.N
  • Postdoctoral Fellowship at Harvard Medical School
  • PhD at KAIST
  • BS/MS at College of Pharmacy, Seoul National Univ.
Key Performances
  • Development of synthetic peptide drugs (US IND)
  • Development and approval of K-CAB for treating GI disease
  • Clinical development of multiple biologics
닫기

Chungmin Lee Ph.D.

CTO / Head of R&D Center

Chungmin has served as IMB’s Chief Technology Officer since its inception and brings over 18 years of scientific excellence in biologics R&D. Prior to IMB, she led early discovery programs upto BLA for numerous biologics at HK inno.N.

Background
  • Leader of Antibody Research Group at HK inno.N
  • BS/MS/PhD at Yonsei University
Key Performances
  • Development of various biologics (BLA)
  • GMP facility process development
닫기

Insoo Jung Ph.D

COO & CBO / Head of Business Operation

Insoo has served as IMB’s COO & CBO since its inception. During his time at KEIT (Korea Evaluation Institute of Industrial Technology) for over 16 years, he led technology evaluation of biotech companies striving to be listed on KOSDAQ. Having completed his postdoctoral fellowship at NIH in the US, he brings a vast knowledge in global new drug development business to IMB.

Background
  • Senior Researcher at KEIT
  • Adjunct professor at Ajou University
  • Postdoctoral Fellow at NIH (US)
  • Ph.D. at Korea University
Key Performances
  • R&D planning and technology evaluation for KOSDAQ IPO
  • KMDF corporation establishment and strategic planning
  • BD contact : insoo.jung@imbiologics.com
  • BD contact : jinwook.kim@imbiologics.com
닫기

Wanjun Kim Master of Business A

Chief of Management Support (CFO)

Background
  • Head of Management Support Division, IMBiologics
  • GoBioLab Management Support Director (CFO)
  • CJ/Kolmar Korea Management Strategy Team Leader
Key Performances
  • GoBioLab KOSDAQ IPO
  • Listed corporation operation and management
닫기

Jiyeon Hong Ph.D.

Head of Business Development

Background
  • IMBiologics, Head of Business Development
  • Genome Opinion, Head of Business Development
  • Daewoong, Open collaboration leader
  • University of Texas Health Science Center at Houston MD Anderson Cancer Center , Ph.D.
Key Performances
  • License in, Partnering
  • Autoimmune team Research BD
  • BD contact : jiyeon.hong@imbiologics.com
닫기

Hong Jai Lee Ph.D.

Leader of Platform Research

Background
  • BS/MS/PhD at Seoul National University
Key Performances
  • Leader of Platform Research at HK inno.N
  • Antibody development at CJ Healthcare
닫기

Eunyoung Lee MD, Ph.D.

Scientific Advisory Board (SAB) member

Background
  • Seoul National University Hospital (SNUH) / Prefessor in Department of Rheumatology
  • SNUH / Head of spinal tumor center
  • Korean College of Rheumatology / Chairman of Spinal arthritis Research Society
  • Weill Cornell Medicine / Training for Special Surgery
  • University of Ulsan College of Medicine / Ph.D.
  • Kyunghee University School of Medicine / M.S.,
Key Performances
  • APLAR congress / Young Scientist Award
  • AGOR meeting / Young Scientist Award
  • Leading multiple global clinical trial (Phase I & II)
닫기

Chulho Park Ph.D.

Scientific Advisory Board (SAB) member

Background
  • Oncotelic Therapeutics, Inc./ CTO
  • MabPrex, Inc. / Founder, President & CEO
  • Eli Lilly & Company /Research Advisor
  • Applied Molecular Evolution / Principal Research Scientist
  • Stanford University / Postdoctoral Fellow
  • Korea University / Ph.D.
Key Performances
  • Serial entrepreneur with biopharmaceutical R&D
  • Leadership experience across diverse biotech and pharma settings
  • Leading CMC/Manufacturing/BD groups
  • Leading multiple therapeutic antibodies & small molecule drugs
  • President(CEO) : Gyongsik Ha
  • 260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea